Alex Thurman Sells 10,000 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 10,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $155.00, for a total transaction of $1,550,000.00. Following the completion of the sale, the chief financial officer directly owned 43,681 shares of the company’s stock, valued at approximately $6,770,555. This trade represents a 18.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Glaukos Stock Up 0.1%

GKOS stock opened at $152.94 on Wednesday. Glaukos Corporation has a one year low of $73.16 and a one year high of $156.60. The firm has a market cap of $8.98 billion, a PE ratio of -46.63 and a beta of 0.75. The firm’s 50 day moving average price is $133.06 and its 200-day moving average price is $121.23. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.12. The company had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm’s revenue for the quarter was up 41.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.22) earnings per share. On average, equities research analysts anticipate that Glaukos Corporation will post -0.57 EPS for the current year.

Hedge Funds Weigh In On Glaukos

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. First Horizon Corp increased its stake in Glaukos by 1,715.4% during the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 223 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Glaukos in the fourth quarter valued at approximately $28,000. Larson Financial Group LLC grew its holdings in shares of Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 132 shares in the last quarter. Parallel Advisors LLC grew its holdings in shares of Glaukos by 159.2% in the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 226 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in Glaukos by 111.4% during the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 215 shares during the period. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on GKOS. Wall Street Zen upgraded shares of Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Needham & Company LLC increased their target price on shares of Glaukos from $136.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. William Blair reiterated an “outperform” rating on shares of Glaukos in a research report on Tuesday, May 26th. Stifel Nicolaus set a $170.00 price target on shares of Glaukos in a research note on Thursday, April 30th. Finally, Citigroup upped their price objective on shares of Glaukos from $162.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $151.77.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.